Physician profile
Nicole E Cash
NPI 1659774909
$1,201.78
in general payments reported to CMS, 2019-2025
15 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.24 · 2022: $62.30 · 2023: $416 · 2024: $219 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $299.73 | 2021-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Glaxosmithkline, LLC. | $240.32 | 2022-2025 | Bexsero, Pediarix, Penmenvy |
| Phadia US INC. | $224.56 | 2023-2025 | Immunocap |
| Seqirus USA INC | $74.87 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $56.79 | 2025 | |
| Kaleo, INC. | $55.18 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $43.04 | 2025 | Neffy |
| Corium, LLC | $38.12 | 2024 | Azstarys |
| Cranial Technologies, INC | $35.78 | 2023-2025 | Doc Band |
| Astrazeneca Pharmaceuticals Lp | $34.51 | 2023-2024 | Flumist Quadrivalent |
| Pfizer INC. | $29.27 | 2023-2024 | |
| Verrica Pharmaceuticals INC. | $20.20 | 2025 | Ycanth |
| Krystal Biotech INC | $19.29 | 2025 | Vyjuvek |
| Abbvie INC. | $16.92 | 2021 | |
| Boston Scientific Corporation | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Cash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.